Tekmira, Bristol-Myers Squibb Expand Collaboration

Bristol-Myers Squibb will now evaluate Tekmira's new lipid nanoparticles for the delivery of siRNA to tumors and tissues outside of the liver.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories